Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Zydus Lifesciences Limited Press Release Dec 06 2023

· Issued by Zydus Lifesciences Limited via NSE India

Filed with NSE · · 3 pages · English

Summary by 6ix AI

This product has the potential to be the first FDA-approved treatment for Menkes disease, with ongoing submission processes expected to conclude in the near future. The press release emphasizes the significance of this development for patients suffering from this rare condition.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 06, 2023, titled "Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases